Caribou Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 102.07 million compared to USD 99.42 million a year ago. Basic loss per share from continuing operations was USD 1.38 compared to USD 1.64 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 USD | -6.29% |
|
-16.75% | -71.38% |
Jun. 04 | US Equities Markets Close Mixed Monday as US Manufacturing Contracts | MT |
Jun. 04 | HC Wainwright Adjusts Price Target on Caribou Biosciences to $9 From $24, Maintains Buy Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-71.38% | 148M | |
+34.01% | 51.07B | |
+34.49% | 38.61B | |
-8.02% | 38.78B | |
-8.98% | 27.32B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- CRBU Stock
- News Caribou Biosciences, Inc.
- Caribou Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023